Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07528352) titled 'External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL' on April 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Utah
Condition:
Diffuse Large B Cell Lymphoma
Intervention:
Drug: Epcoritamab
Drug: Glofitamab
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: May 2026
Target Sample Size: 12
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07528352...